French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that it has received fast track designation from the US Food and Drug Administration (FDA) for its mRNA vaccine candidate aimed at preventing chlamydia infection.
This designation reflects the vaccine's potential to address a serious condition and meet an unmet public health need.
The vaccine is designed to protect against primary and recurrent genital tract infections caused by Chlamydia trachomatis. Following promising pre-clinical results, Sanofi plans to initiate a phase 1/2 clinical study in the coming days to evaluate the vaccine's immunogenicity and safety in adults aged 18 to 29 years.
Chlamydia, a bacterial infection affecting the reproductive tract, can lead to infertility and pregnancy complications, with 129 million cases reported globally in 2020. Despite the availability of antibiotic treatment, over 80% of cases are asymptomatic, resulting in undiagnosed and untreated infections that contribute to ongoing transmission.
Sanofi's development of this vaccine is part of the Translational Science Hub, a collaboration with the Queensland Government, Griffith University and the University of Queensland, connecting researchers in Australia with Sanofi scientists in France and the United States.
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
Avance Biosciences registers with CLIA program
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate